National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 1 of 1 Research Studies DisplayedChase BA, Semenov I, Rubin S
Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: a retrospective clinical and genetic study.
This study’s objective was to evaluate response to anti-calcitonin gene-related peptide (CGRP) migraine preventives in a real-world community cohort of persons living with migraine and to identify clinical and genetic characteristics associated with efficacious response. The authors looked at users of erenumab-aooeb, fremanezumab-vrfm, and galcanezumab-gnl and their reasons for stopping or starting these medications. No difference was seen at either first or second follow-ups between galcanezumab and fremanezumab or fremanezumab and erenumab. There was a decrease in MDM at follow-up that was generally proportional to baseline MDM, larger in females, and increased with months on medication, with the reasons for switching or stopping a preventive varying between medications and was often related to cost or insurance coverage. At both follow-ups, patient tolerance and continued use were high and similar across preventives.
AHRQ-funded; HS024057.
Citation: Chase BA, Semenov I, Rubin S .
Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: a retrospective clinical and genetic study.
Headache 2024 Jan; 64(1):68-92. doi: 10.1111/head.14655.AHRQ-funded; HS024057..
Keywords: Neurological Disorders, Medication